tVNS Technologies

tVNS Technologies operates in medical devices, digital health, and neuromodulation, with a focused offering in transcutaneous vagus nerve stimulation. Its tVNS® E is described as an EU MDR Class IIa-approved device, and the company characterizes it as the only non-invasive vagus nerve stimulation device with that approval. The tVNS® R extends the proposition toward clinical and academic research through adjustable stimulation, study-specific configurations, data capture, patient feedback tools, sham options, and fMRI-compatible electrodes. Supporting apps, trigger integration, and API-related capabilities add a software and protocol layer around the hardware. Its apparent point of distinction is the combination of a regulated device for clinical use and a configurable research platform, rather than evidence of scale, broad product coverage, or a quantified commercial lead.

Founded on Jan 1, 2022, tVNS Technologies has developed a product set spanning the tVNS® E medical device, the tVNS® R research system, apps, stimulation accessories, and software for external-trigger integration. The clearest potential inflection in its trajectory is the move from a single-device proposition toward a broader platform that can serve both clinical users and research teams. Its research features—including configurable stimulation, data capture, sham options, and fMRI-compatible electrodes—suggest an effort to support study workflows as well as device use. No funding amount or valuation can be established. Consequently, the evidence supports a view of focused product development and platform expansion, but not a confident claim of accelerating growth. Future assessment would benefit from dated launch, study, sales, and financing milestones.